These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 27771243)

  • 1. American Brachytherapy Society Task Group Report: Combination of brachytherapy and external beam radiation for high-risk prostate cancer.
    Spratt DE; Soni PD; McLaughlin PW; Merrick GS; Stock RG; Blasko JC; Zelefsky MJ
    Brachytherapy; 2017; 16(1):1-12. PubMed ID: 27771243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.
    Morris WJ; Tyldesley S; Rodda S; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):275-285. PubMed ID: 28262473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.
    Shilkrut M; Merrick GS; McLaughlin PW; Stenmark MH; Abu-Isa E; Vance SM; Sandler HM; Feng FY; Hamstra DA
    Cancer; 2013 Feb; 119(3):681-90. PubMed ID: 22893254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
    Wedde TB; Småstuen MC; Brabrand S; Fosså SD; Kaasa S; Tafjord G; Russnes KM; Hellebust TP; Lilleby W
    Radiother Oncol; 2019 Mar; 132():211-217. PubMed ID: 30389241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival outcomes of combined external beam radiotherapy and brachytherapy vs. brachytherapy alone for intermediate-risk prostate cancer patients using the National Cancer Data Base.
    Amini A; Jones BL; Jackson MW; Rusthoven CG; Maroni P; Kavanagh BD; Raben D
    Brachytherapy; 2016; 15(2):136-46. PubMed ID: 26825856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives.
    Gondi V; Deutsch I; Mansukhani M; O'Toole KM; Shah JN; Schiff PB; Katz AE; Benson MC; Goluboff ET; Ennis RD
    Urology; 2007 Mar; 69(3):541-6. PubMed ID: 17382161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy.
    Shilkrut M; McLaughlin PW; Merrick GS; Vainshtein JM; Feng FY; Hamstra DA
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):721-8. PubMed ID: 23664325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
    Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variations in patterns of concurrent androgen deprivation therapy use based on dose escalation with external beam radiotherapy vs. brachytherapy boost for prostate cancer.
    Mohiuddin JJ; Narayan V; Venigalla S; Vapiwala N
    Brachytherapy; 2019; 18(3):322-331. PubMed ID: 30862436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No apparent benefit at 5 years from a course of neoadjuvant/concurrent androgen deprivation for patients with prostate cancer treated with a high total radiation dose.
    Martinez A; Galalae R; Gonzalez J; Mitchell C; Gustafson G; Kovacs G
    J Urol; 2003 Dec; 170(6 Pt 1):2296-301. PubMed ID: 14634400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Outcomes in Very High-risk Prostate Cancer Treated by Dose-escalated and Combined-Modality Radiation Therapy.
    Shilkrut M; McLaughlin PW; Merrick GS; Vainshtein JM; Hamstra DA
    Am J Clin Oncol; 2016 Apr; 39(2):181-8. PubMed ID: 24517957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809.
    Hurwitz MD; Halabi S; Archer L; McGinnis LS; Kuettel MR; DiBiase SJ; Small EJ
    Cancer; 2011 Dec; 117(24):5579-88. PubMed ID: 22535500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. External beam radiation therapy and a low-dose-rate brachytherapy boost without or with androgen deprivation therapy for prostate cancer.
    Strom TJ; Hutchinson SZ; Shrinath K; Cruz AA; Figura NB; Nethers K; Biagioli MC; Fernandez DC; Heysek RV; Wilder RB
    Int Braz J Urol; 2014; 40(4):474-83. PubMed ID: 25251952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients.
    Joseph N; Taylor C; O'Hara C; Choudhury A; Elliott T; Logue J; Wylie J
    Radiother Oncol; 2016 Nov; 121(2):299-303. PubMed ID: 28029404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
    Rodda S; Tyldesley S; Morris WJ; Keyes M; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):286-295. PubMed ID: 28433432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brachytherapy or conformal external radiotherapy for prostate cancer: a single-institution matched-pair analysis.
    Pickles T; Keyes M; Morris WJ
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):43-9. PubMed ID: 19570619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy.
    Yang DD; Muralidhar V; Mahal BA; Nguyen PL; Devlin PM; King MT; Orio PF
    Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):53-58. PubMed ID: 29254781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brachytherapy Boost Utilization and Survival in Unfavorable-risk Prostate Cancer.
    Johnson SB; Lester-Coll NH; Kelly JR; Kann BH; Yu JB; Nath SK
    Eur Urol; 2017 Nov; 72(5):738-744. PubMed ID: 28688613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.